2mg CS0159

DRUG2 trials

Sponsors

Cascade Pharmaceuticals, Inc

Conditions

Primary Biliary CholangitisPrimary Biliary Cholangitis (PBC)

Phase 2

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Active, not recruitingNCT05896124

Cascade Pharmaceuticals, IncPrimary Biliary Cholangitis (PBC)

Start: 2023-08-07End: 2026-03-15Updated: 2026-03-13

Phase 3

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

RecruitingNCT07282353

Cascade Pharmaceuticals, IncPrimary Biliary Cholangitis

Start: 2025-12-01End: 2028-01-06Target: 135Updated: 2026-07-08